1. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that the company will deliver a corporate presentation at the 11th Annual Leerink Global Healthcare Conference (February 14-18, 2022). The presentation will take place virtually on Wednesday, February 16, 2022 at 8 am ET. Interested parties can register to listen to the presentation via the public link here or access via the Investor section of the Aurinia corporate website - www.auriniapharma.com, under "News/Events."

    ABOUT AURINIA

    Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced…

    View Full Article
  2. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that members of the management team will participate in two upcoming virtual investor conferences.

    • H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday, January 10, 2022, beginning at 7:00 a.m. EST thru Thursday, January 13, 2022 (access here)
    • J.P Morgan 40th Annual Healthcare Conference. Presentation to be hosted on Thursday, January 13, 2022 at 9:45 am EST (access here)

    Interested parties can also register and access these presentations under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com.

    ABOUT AURINIA

    Aurinia is a fully integrated biopharmaceutical company focused…

    View Full Article
  3. - Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy -

    - Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroids alone, the active study control -

    - Similar to the active control, the voclosporin-treated group maintained stable renal function at the end of the study -

    - Aurinia to host conference call today, December 9, at 8:30 a.m. EST -

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA…

    View Full Article
  4. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees on demand (link here) beginning on Thursday, November 18 at 8 am GMT/3 am EST through Friday, November 19 at 5 pm GMT/12 pm EST.

    Interested parties can also register and access the on-demand webcast through the Investor section of the Aurinia corporate website - www.auriniapharma.com, under "News/Events."

    ABOUT AURINIA

    Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious…

    View Full Article
  5. $14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021)

    Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage

    Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline

    Conference call to be hosted today at 8:30 a.m. ET

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.

    Aurinia achieved third quarter revenue of $14.7 million, with nine months ended September 30, 2021 revenue of $22.2 million and maintains its previously stated annual revenue…

    View Full Article